



Carlos Forray, et al.
Serial No.: 10/029,314
Filed: December 20, 2001
Page 3

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-167: (Canceled)

Claim 169 (Currently amended): A method of treating an eating disorder or obesity in a subject which comprises administering to the subject a therapeutically effective amount of an MCH1 antagonist which inhibits the activation of the MCH1 receptor with an antagonist potency which is at least 10-fold greater than the antagonist potency with which the MCH1 antagonist inhibits the activation of the NPY1 receptor.

Claim 170 (Previously presented): A method of claim 169, wherein the MCH1 antagonist additionally inhibits the activation of the MCH1 receptor with an antagonist potency which is at least 30-fold greater than the antagonist potency with which the MCH1 antagonist inhibits the activation of each of the 5-HT2C and MC-4 receptors.

Claim 171 (Currently amended): A method of claim 170, wherein the MCH1 antagonist additionally inhibits the activation of the MCH1 receptor with an antagonist potency which is at least 10-fold greater than the antagonist potency with which the MCH1 antagonist inhibits the activation of each of the ~~NPY1~~, NPY5, GALR1, GALR2, and GALR3 receptors.

Claim 172 (Previously presented): A method of claim 170, wherein the MCH1 antagonist additionally inhibits the activation of the MCH1 receptor with an antagonist potency which is at least 100-fold greater than the antagonist potency with which the MCH1 antagonist inhibits the activation of each of the 5-HT2C and MC-4 receptors.

Claim 173 (Previously presented): A method of claim 172, wherein the MCH1 antagonist additionally inhibits the activation of the MCH1 receptor with an antagonist potency which is at

RECEIVED

FEB 12 2004

TECH CENTER 1000/2900

least 100-fold greater than the antagonist potency with which the MCH1 antagonist inhibits the activation of each of the NPY1, NPY5, GALR1, GALR2, and GALR3 receptors.

Claim 174 (Previously presented): A method of claim 169, wherein the MCH1 antagonist additionally inhibits the activation of the MCH1 receptor with an antagonist potency which is at least 30-fold greater than the binding affinity with which the MCH1 antagonist binds to each of the 5-HT2C and MC-4 receptors.

Claim 175 (Currently amended): A method of claim 174, wherein the MCH1 antagonist additionally inhibits the activation of the MCH1 receptor with an antagonist potency which is at least 10-fold greater than the binding affinity with which the MCH1 antagonist binds to each of the ~~NPY1~~, NPY5, GALR1, GALR2, and GALR3 receptors.

Claim 176 (Previously presented): A method of claim 174, wherein the MCH1 antagonist additionally inhibits the activation of the MCH1 receptor with an antagonist potency which is at least 100-fold greater than the binding affinity with which the MCH1 antagonist binds to each of the 5-HT2C and MC-4 receptors.

Claim 177 (Previously presented): A method of claim 176, wherein the MCH1 antagonist additionally inhibits the activation of the MCH1 receptor with an antagonist potency which is at least 100-fold greater than the binding affinity with which the MCH1 antagonist binds to each of the NPY1, NPY5, GALR1, GALR2, and GALR3 receptors.

Claim 178 (Previously presented): A method of claim 169, wherein the MCH1 antagonist additionally binds to the MCH1 receptor with a binding affinity which is at least 30-fold greater than the binding affinity with which the MCH1 antagonist binds to each of the 5-HT2C and MC-4 receptors.

Claim 179 (Currently amended): A method of claim 178, wherein the MCH1 antagonist additionally binds to the MCH1 receptor with a binding affinity which is at least 10-fold greater than the binding affinity with which the MCH1 antagonist binds to each of the ~~NPY1~~, NPY5, GALR1, GALR2, and GALR3 receptors.

Claim 180 (Previously presented): A method of claim 178, wherein the MCH1 antagonist additionally binds to the MCH1 receptor with a binding affinity which is at least 100-fold greater

than the binding affinity with which the MCH1 antagonist binds to each of the 5-HT_{2C} and MC-4 receptors.

Claim 181 (Previously presented): A method of claim 180, wherein the MCH1 antagonist additionally binds to the MCH1 receptor with a binding affinity which is at least 100-fold greater than the binding affinity with which the MCH1 antagonist binds to each of the NPY₁, NPY₅, GALR₁, GALR₂, and GALR₃ receptors.

Claim 182 (Previously presented): A method of claim 169, wherein the MCH1 antagonist additionally binds to the MCH1 receptor with a binding affinity which is at least 30-fold greater than the binding affinity with which the MCH1 antagonist binds to the dopamine D₂ receptor.

Claim 183 (Previously presented): A method of claim 169, wherein the MCH1 antagonist additionally binds to the MCH1 receptor with a binding affinity which is at least 30-fold greater than the binding affinity with which the MCH1 antagonist binds to the histamine H₁ receptor.

Claim 184 (Previously presented): A method of claim 169, wherein the MCH1 antagonist additionally binds to the MCH1 receptor with a binding affinity which is at least 100-fold greater than the binding affinity with which the MCH1 antagonist binds to the dopamine D₂ receptor.

Claim 185 (Previously presented): A method of claim 169, wherein the MCH1 antagonist additionally binds to the MCH1 receptor with a binding affinity which is at least 100-fold greater than the binding affinity with which the MCH1 antagonist binds to the histamine H₁ receptor.

Claim 186 (Previously presented): A method of claim 169, wherein the MCH1 antagonist additionally binds to the MCH1 receptor with a binding affinity which is at least 200-fold greater than the binding affinity with which the MCH1 antagonist binds to the dopamine D₂ receptor.

Claim 187 (Previously presented): A method of claim 169, wherein the MCH1 antagonist additionally binds to the MCH1 receptor with a binding affinity which is at least 200-fold greater than the binding affinity with which the MCH1 antagonist binds to the histamine H₁ receptor.

Claim 188 (Previously presented): A method of claim 169, wherein

the MCH1 antagonist additionally binds to the MCH1 receptor with a binding affinity which is at least 10-fold greater than the binding affinity with which the MCH1 antagonist binds to the α_{1A} adrenoceptor.

Claim 189 (Previously presented): A method of claim 169, wherein the MCH1 antagonist additionally binds to the MCH1 receptor with a binding affinity which is at least 100-fold greater than the binding affinity with which the MCH1 antagonist binds to the α_{1A} adrenoceptor.

Claim 190 (Previously presented): A method of claim 169, wherein the MCH1 antagonist additionally binds to the α_{1A} adrenoceptor with a binding affinity which is no more than 10-fold greater than the binding affinity with which the MCH1 antagonist binds to the MCH1 receptor.

Claim 191 (Previously presented): A method of claim 169, wherein the MCH1 antagonist additionally binds to the α_{1A} adrenoceptor with a binding affinity which is no more than 100-fold greater than the binding affinity with which the MCH1 antagonist binds to the MCH1 receptor.

Claim 192 (Previously presented): A method of treating an eating disorder in a subject which comprises administering to the subject a therapeutically effective amount of an MCH1 agonist which activates the MCH1 receptor.

Claim 193 (Previously presented): A method of claim 182, wherein the MCH1 agonist additionally activates the MCH1 receptor with an agonist potency which is at least 30-fold greater than the agonist potency with which the MCH1 agonist activates each of the 5-HT_{2C} and MC-4 receptors.

Claim 194 (Previously presented): A method of claim 183, wherein the MCH1 agonist additionally activates the MCH1 receptor with an agonist potency which is at least 10-fold greater than the agonist potency with which the MCH1 agonist activates each of the NPY₁, NPY₅, GALR₁, GALR₂, and GALR₃ receptors.

Claim 195 (Previously presented): A method of claim 183, wherein the MCH1 agonist additionally activates the MCH1 receptor with an agonist potency which is at least 100-fold greater than the agonist potency with which the MCH1 agonist activates each of the 5-HT_{2C} and MC-4 receptors.

Claim 196 (Previously presented): A method of claim 185, wherein

Carlos Forray, et al.
Serial No.: 10/029,314
Filed: December 20, 2001
Page 7

the MCH1 agonist additionally activates the MCH1 receptor with an agonist potency which is at least 100-fold greater than the agonist potency with which the MCH1 agonist activates each of the NPY1, NPY5, GALR1, GALR2, and GALR3 receptors.

Claim 197 (Previously amended): A method of claim 192, wherein the eating disorder is anorexia nervosa.

Claims 198-207 (Canceled)